Drongen, Belgium

Lieve Nuytinck

USPTO Granted Patents = 1 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Lieve Nuytinck: Innovator in Neurological Disease Risk Assessment

Introduction

Lieve Nuytinck is a notable inventor based in Drongen, Belgium. He has made significant contributions to the field of medical diagnostics, particularly in assessing the risk of developing neurological diseases. His innovative work has the potential to impact many lives by providing early detection methods for serious conditions.

Latest Patents

Lieve Nuytinck holds a patent for a "Method for determining the risk of developing a neurological disease." This patent focuses on methods and kits designed to determine whether a subject is at risk of developing neurological diseases such as Alzheimer's disease and multiple sclerosis. The techniques are based on the detection of one or more nucleic acid variants in the MBL gene of the subject. This advancement represents a significant step forward in the early diagnosis and management of these debilitating conditions.

Career Highlights

Lieve Nuytinck is associated with Abbott Healthcare Products B.V., a company known for its commitment to healthcare innovation. His work at Abbott has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research in neurological health.

Collaborations

Lieve has worked alongside Eugeen Vanmechelen, a talented female colleague, who shares his passion for advancing medical science. Their collaboration has fostered an environment of innovation and creativity, leading to significant advancements in their field.

Conclusion

Lieve Nuytinck's contributions to the field of neurological disease risk assessment highlight the importance of innovation in healthcare. His patent and ongoing work at Abbott Healthcare Products B.V. demonstrate his commitment to improving patient outcomes through early detection and intervention.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…